Paradigm Biopharmaceuticals Ltd (PAR) — Cash Flow-to-Debt Ratio
Paradigm Biopharmaceuticals Ltd (PAR) has a Cash Flow-to-Debt Ratio of -1.15x as of December 2025, meaning its operating cash flow of AU$-19.65 Million could theoretically repay -1% of its total liabilities (AU$17.16 Million) in one year. See PAR net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Paradigm Biopharmaceuticals Ltd Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Paradigm Biopharmaceuticals Ltd across 12 annual periods. Also explore Paradigm Biopharmaceuticals Ltd net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Paradigm Biopharmaceuticals Ltd (2014–2025)
Year-by-year debt coverage analysis for Paradigm Biopharmaceuticals Ltd. For market capitalisation and broader financial context, see PAR company net worth.
| Year | CF-to-Debt Ratio | Operating CF (AUD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.72x | AU$-15.99 Million | AU$3.39 Million | ▲ +74.3% |
| 2024 | -18.40x | AU$-65.94 Million | AU$3.58 Million | ▼ -445.3% |
| 2023 | -3.37x | AU$-45.19 Million | AU$13.39 Million | ▲ +12.2% |
| 2022 | -3.84x | AU$-32.21 Million | AU$8.38 Million | ▲ +28.2% |
| 2021 | -5.36x | AU$-34.93 Million | AU$6.52 Million | ▼ -122.1% |
| 2020 | -2.41x | AU$-10.09 Million | AU$4.18 Million | ▼ -2.5% |
| 2019 | -2.35x | AU$-6.37 Million | AU$2.70 Million | ▲ +48.1% |
| 2018 | -4.53x | AU$-6.01 Million | AU$1.33 Million | ▲ +3.2% |
| 2017 | -4.68x | AU$-4.47 Million | AU$955.29K | ▼ -45.7% |
| 2016 | -3.21x | AU$-3.59 Million | AU$1.12 Million | ▼ -54.1% |
| 2015 | -2.08x | AU$-1.20 Million | AU$577.33K | ▼ -24.4% |
| 2014 | -1.68x | AU$-617.72K | AU$368.67K | — |